LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Search

Twist Bioscience Corp

Fechado

SetorSaúde

31.08 4.72

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.33

Máximo

31.81

Indicadores-chave

By Trading Economics

Rendimento

-48M

-27M

Vendas

3M

99M

EPS

-0.45

Margem de lucro

-27.41

Funcionários

979

EBITDA

-2.3M

-26M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+27.26% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-43M

1.8B

Abertura anterior

26.36

Fecho anterior

31.08

Sentimento de Notícias

By Acuity

50%

50%

167 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de dez. de 2025, 23:21 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 de dez. de 2025, 23:14 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 de dez. de 2025, 22:01 UTC

Grandes Movimentos do Mercado

Costco Wholesale Reports Higher Monthly Sales

3 de dez. de 2025, 21:38 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 de dez. de 2025, 23:59 UTC

Conversa de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 de dez. de 2025, 23:49 UTC

Conversa de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 de dez. de 2025, 23:13 UTC

Conversa de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 de dez. de 2025, 23:10 UTC

Ganhos

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 de dez. de 2025, 23:08 UTC

Conversa de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 de dez. de 2025, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 de dez. de 2025, 22:59 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB to Buy PC Financial From Loblaw for About $573.5M

3 de dez. de 2025, 22:45 UTC

Conversa de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 de dez. de 2025, 22:20 UTC

Ganhos

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 de dez. de 2025, 22:19 UTC

Ganhos

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 de dez. de 2025, 22:17 UTC

Ganhos

Salesforce Working to Add Voice to Agentforce, CEO Says

3 de dez. de 2025, 22:16 UTC

Ganhos

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 de dez. de 2025, 22:15 UTC

Ganhos

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 de dez. de 2025, 22:10 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 de dez. de 2025, 22:09 UTC

Aquisições, Fusões, Aquisições de Empresas

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

3 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

3 de dez. de 2025, 21:49 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:23 UTC

Ganhos

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 de dez. de 2025, 21:19 UTC

Ganhos

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:06 UTC

Ganhos

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 de dez. de 2025, 21:04 UTC

Ganhos

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 de dez. de 2025, 21:03 UTC

Ganhos

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

27.26% parte superior

Previsão para 12 meses

Média 38 USD  27.26%

Máximo 42 USD

Mínimo 32 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

167 / 374 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat